Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

Microbiota and mucosal defense in IBD: an update.

Stange EF, Schroeder BO.

Expert Rev Gastroenterol Hepatol. 2019 Oct 11:1-14. doi: 10.1080/17474124.2019.1671822. [Epub ahead of print]

PMID:
31603356
2.

Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide.

Wendler J, Schroeder BO, Ehmann D, Koeninger L, Mailänder-Sánchez D, Lemberg C, Wanner S, Schaller M, Stange EF, Malek NP, Weidenmaier C, LeibundGut-Landmann S, Wehkamp J.

Sci Rep. 2019 Mar 6;9(1):3640. doi: 10.1038/s41598-019-40216-2.

3.

Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's Disease.

Klag T, Courth L, Ostaff MJ, Ott G, Stange EF, Malek NP, Seifarth W, Wehkamp J.

Inflamm Intest Dis. 2019 Feb;3(3):125-137. doi: 10.1159/000494026. Epub 2018 Nov 21.

4.

Paneth cell α-defensins HD-5 and HD-6 display differential degradation into active antimicrobial fragments.

Ehmann D, Wendler J, Koeninger L, Larsen IS, Klag T, Berger J, Marette A, Schaller M, Stange EF, Malek NP, Jensen BAH, Wehkamp J.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. Epub 2019 Feb 11.

5.

Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue.

Stebe-Frick S, Ostaff MJ, Stange EF, Malek NP, Wehkamp J.

Sci Rep. 2018 Aug 27;8(1):12886. doi: 10.1038/s41598-018-31125-x.

6.

Recent advances and emerging therapies in the non-surgical management of ulcerative colitis.

Wehkamp J, Stange EF.

F1000Res. 2018 Aug 7;7. pii: F1000 Faculty Rev-1207. doi: 10.12688/f1000research.15159.1. eCollection 2018. Review.

7.

β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor.

Klag T, Thomas M, Ehmann D, Courth L, Mailänder-Sanchez D, Weiss TS, Dayoub R, Abshagen K, Vollmar B, Thasler WE, Stange EF, Berg CP, Malek NP, Zanger UM, Wehkamp J.

Front Immunol. 2018 Jul 27;9:1735. doi: 10.3389/fimmu.2018.01735. eCollection 2018.

8.

Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohn's Disease.

Jaeger SU, Schaeffeler E, Winter S, Tremmel R, Schölmerich J, Malek N, Stange EF, Schwab M, Wehkamp J.

Front Pharmacol. 2018 Jul 16;9:764. doi: 10.3389/fphar.2018.00764. eCollection 2018.

9.

[German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) position statement on endoscopic decompression in acute Ileus].

Götz M, Braun G, Jakobs R, Messmann H, Stange EF, Lerch MM; für die Mitglieder der DGVS-Kommission im Anhang.

Z Gastroenterol. 2017 Dec;55(12):1499-1508. doi: 10.1055/s-0043-120351. Epub 2017 Dec 6. Review. German.

PMID:
29212105
10.

In the Wnt of Paneth Cells: Immune-Epithelial Crosstalk in Small Intestinal Crohn's Disease.

Armbruster NS, Stange EF, Wehkamp J.

Front Immunol. 2017 Sep 26;8:1204. doi: 10.3389/fimmu.2017.01204. eCollection 2017. Review.

11.

[A 20-year-old woman with ulcerative colitis and acute liver failure].

Forker R, Escher M, Stange EF.

Internist (Berl). 2017 Sep;58(9):982-989. doi: 10.1007/s00108-017-0205-4. German.

PMID:
28271269
12.

Recent advances in understanding and managing Crohn's disease.

Stange EF, Wehkamp J.

F1000Res. 2016 Dec 21;5:2896. doi: 10.12688/f1000research.9890.1. eCollection 2016. Review.

13.

Improvement of a 'Leaky' Intestinal Barrier.

Stange EF.

Dig Dis. 2017;35(1-2):21-24. doi: 10.1159/000449078. Epub 2017 Feb 1. Review.

PMID:
28147355
14.

In Reply.

Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF.

Dtsch Arztebl Int. 2016 Jul 1;113(26):462. doi: 10.3238/arztebl.2016.0462b. No abstract available.

15.

Inflammatory Bowel Disease.

Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF.

Dtsch Arztebl Int. 2016 Feb 5;113(5):72-82. doi: 10.3238/arztebl.2016.0072. Review.

16.

Medical Therapy of Perianal Crohn's Disease.

Klag T, Goetz M, Stange EF, Wehkamp J.

Viszeralmedizin. 2015 Aug;31(4):265-72. doi: 10.1159/000434664. Epub 2015 Jul 29. Review.

17.

Crohn's disease-derived monocytes fail to induce Paneth cell defensins.

Courth LF, Ostaff MJ, Mailänder-Sánchez D, Malek NP, Stange EF, Wehkamp J.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14000-5. doi: 10.1073/pnas.1510084112. Epub 2015 Oct 28.

18.

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues.

Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K, Büning J.

J Crohns Colitis. 2016 Jan;10(1):31-7. doi: 10.1093/ecco-jcc/jjv175. Epub 2015 Sep 28.

PMID:
26419459
19.

Management of Crohn's disease - are guidelines transferred to clinical practice?

Klag T, Stange EF, Wehkamp J.

United European Gastroenterol J. 2015 Aug;3(4):371-80. doi: 10.1177/2050640615580228.

20.

Chronic Heavy Alcohol Use is Associated with Upregulated Paneth Cell Antimicrobials in Gastric Mucosa.

Ostaff MJ, Schäfer C, Courth L, Stebe SR, Ott G, Stange EF, Wehkamp J.

Clin Transl Gastroenterol. 2015 Jul 16;6:e103. doi: 10.1038/ctg.2015.26.

21.

[Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease" 2014].

Preiß JC, Bokemeyer B, Buhr HJ, Dignaß A, Häuser W, Hartmann F, Herrlinger KR, Kaltz B, Kienle P, Kruis W, Kucharzik T, Langhorst J, Schreiber S, Siegmund B, Stallmach A, Stange EF, Stein J, Hoffmann JC; German Society of Gastroenterology.

Z Gastroenterol. 2014 Dec;52(12):1431-84. doi: 10.1055/s-0034-1385199. Epub 2014 Dec 4. German. No abstract available.

PMID:
25474283
22.

Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals.

Renner O, Harsch S, Matysik S, Lütjohann D, Schmitz G, Stange EF.

United European Gastroenterol J. 2014 Jun;2(3):216-25. doi: 10.1177/2050640614527938.

23.

Paneth cell α-defensin 6 (HD-6) is an antimicrobial peptide.

Schroeder BO, Ehmann D, Precht JC, Castillo PA, Küchler R, Berger J, Schaller M, Stange EF, Wehkamp J.

Mucosal Immunol. 2015 May;8(3):661-71. doi: 10.1038/mi.2014.100. Epub 2014 Nov 5.

24.

Association of FXR gene variants with cholelithiasis.

Hirobe-Jahn S, Harsch S, Renner O, Richter D, Müller O, Stange EF.

Clin Res Hepatol Gastroenterol. 2015 Feb;39(1):68-79. doi: 10.1016/j.clinre.2014.07.002. Epub 2014 Sep 18.

PMID:
25242139
25.

[Therapy of chronic inflammatory bowel diseases. Standards, controversies and perspectives].

Herrlinger K, Fellermann K, Stange EF.

Internist (Berl). 2014 Aug;55(8):906-17. doi: 10.1007/s00108-013-3442-1. Review. German.

PMID:
25030498
26.

Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile.

Nuding S, Frasch T, Schaller M, Stange EF, Zabel LT.

Antimicrob Agents Chemother. 2014 Oct;58(10):5719-25. doi: 10.1128/AAC.02542-14. Epub 2014 Jul 14.

27.

TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease.

Beisner J, Teltschik Z, Ostaff MJ, Tiemessen MM, Staal FJ, Wang G, Gersemann M, Perminow G, Vatn MH, Schwab M, Stange EF, Wehkamp J.

Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G487-98. doi: 10.1152/ajpgi.00347.2013. Epub 2014 Jul 3.

28.

Intestinal barrier in inflammatory bowel disease.

Antoni L, Nuding S, Wehkamp J, Stange EF.

World J Gastroenterol. 2014 Feb 7;20(5):1165-79. doi: 10.3748/wjg.v20.i5.1165. Review.

29.

Therapeutic peptides in inflammatory bowel disease.

Herrlinger KR, Stange EF, Fellermann K.

Expert Opin Biol Ther. 2014 Apr;14(4):455-66. doi: 10.1517/14712598.2014.880109. Review.

PMID:
24450849
30.

Gastrointestinal involvement in granulomatosis with polyangiitis and microscopic polyangiitis: histological features and outcome.

Latus J, Koetter I, Fritz P, Kimmel M, Biegger D, Ott G, Stange EF, Amann K, Alscher DM, Braun N.

Int J Rheum Dis. 2014 May;17(4):412-9. doi: 10.1111/1756-185X.12203. Epub 2013 Oct 29.

PMID:
24400862
31.

The debated role for thiopurines in Crohn's disease.

Herrlinger KR, Stange EF.

J Crohns Colitis. 2014 Feb;8(2):172-4. doi: 10.1016/j.crohns.2013.11.026. Epub 2013 Dec 15.

PMID:
24342765
32.

Defective antibacterial barrier in inflammatory bowel disease.

Klag T, Stange EF, Wehkamp J.

Dig Dis. 2013;31(3-4):310-6. doi: 10.1159/000354858. Epub 2013 Nov 14. Review.

PMID:
24246980
33.

The host and the flora.

Nuding S, Antoni L, Stange EF.

Dig Dis. 2013;31(3-4):286-92. doi: 10.1159/000354680. Epub 2013 Nov 14. Review.

PMID:
24246976
34.

Inflammatory bowel diseases. Preface.

Stange EF.

Dig Dis. 2013;31(3-4):269. doi: 10.1159/000354674. Epub 2013 Nov 14. No abstract available.

PMID:
24246973
35.

Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance.

Nuding S, Gersemann M, Hosaka Y, Konietzny S, Schaefer C, Beisner J, Schroeder BO, Ostaff MJ, Saigenji K, Ott G, Schaller M, Stange EF, Wehkamp J.

PLoS One. 2013 Sep 11;8(9):e73867. doi: 10.1371/journal.pone.0073867. eCollection 2013.

36.

Antimicrobial peptides and gut microbiota in homeostasis and pathology.

Ostaff MJ, Stange EF, Wehkamp J.

EMBO Mol Med. 2013 Oct;5(10):1465-83. doi: 10.1002/emmm.201201773. Epub 2013 Aug 23. Review.

37.

Antimicrobial activity of high-mobility-group box 2: a new function to a well-known protein.

Küchler R, Schroeder BO, Jaeger SU, Stange EF, Wehkamp J.

Antimicrob Agents Chemother. 2013 Oct;57(10):4782-93. doi: 10.1128/AAC.00805-13. Epub 2013 Jul 22.

38.

Human colonic mucus is a reservoir for antimicrobial peptides.

Antoni L, Nuding S, Weller D, Gersemann M, Ott G, Wehkamp J, Stange EF.

J Crohns Colitis. 2013 Dec;7(12):e652-64. doi: 10.1016/j.crohns.2013.05.006. Epub 2013 Jun 17.

PMID:
23787054
39.

[Inflammatory bowel disease - the past 50 years].

Stange EF.

Z Gastroenterol. 2013 Apr;51(4):371-7. doi: 10.1055/s-0033-1335146. Epub 2013 Apr 12. German.

PMID:
23585266
40.

Cell-mediated reduction of human β-defensin 1: a major role for mucosal thioredoxin.

Jaeger SU, Schroeder BO, Meyer-Hoffert U, Courth L, Fehr SN, Gersemann M, Stange EF, Wehkamp J.

Mucosal Immunol. 2013 Nov;6(6):1179-90. doi: 10.1038/mi.2013.17. Epub 2013 Apr 10.

41.

Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo.

Becker S, Oelschlaeger TA, Wullaert A, Vlantis K, Pasparakis M, Wehkamp J, Stange EF, Gersemann M.

PLoS One. 2013;8(2):e55620. doi: 10.1371/journal.pone.0055620. Epub 2013 Feb 13. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/13f3d7ee-a72c-4879-bedb-8e73b6b364ac. Vlantis, Katerina [added].

42.

Role of the ABCG8 19H risk allele in cholesterol absorption and gallstone disease.

Renner O, Lütjohann D, Richter D, Strohmeyer A, Schimmel S, Müller O, Stange EF, Harsch S.

BMC Gastroenterol. 2013 Feb 13;13:30. doi: 10.1186/1471-230X-13-30.

43.

Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.

Angelberger S, Schaeffeler E, Teml A, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR, Schwab M, Reinisch W.

Inflamm Bowel Dis. 2013 Mar;19(3):590-8. doi: 10.1097/MIB.0b013e31827eea8b.

PMID:
23388543
44.

Extended abstract: Tacrolimus and cyclosporine in inflammatory bowel disease.

Stange EF.

Dig Dis. 2012;30 Suppl 3:119-20. doi: 10.1159/000342737. Epub 2013 Jan 3. No abstract available.

PMID:
23295702
45.

Inflammatory bowel disease: an impaired barrier disease.

Jäger S, Stange EF, Wehkamp J.

Langenbecks Arch Surg. 2013 Jan;398(1):1-12. doi: 10.1007/s00423-012-1030-9. Epub 2012 Nov 18. Review.

PMID:
23160753
46.

[Human beta-defensin 1: from defence to offence].

Schroeder BO, Stange EF, Wehkamp J.

Z Gastroenterol. 2012 Nov;50(11):1171-5. doi: 10.1055/s-0032-1312865. Epub 2012 Nov 13. Review. German.

PMID:
23150110
47.

More than a marine propeller--the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus.

Troge A, Scheppach W, Schroeder BO, Rund SA, Heuner K, Wehkamp J, Stange EF, Oelschlaeger TA.

Int J Med Microbiol. 2012 Dec;302(7-8):304-14. doi: 10.1016/j.ijmm.2012.09.004. Epub 2012 Nov 4.

PMID:
23131416
48.

Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients.

Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J.

Aliment Pharmacol Ther. 2013 Jan;37(1):129-36. doi: 10.1111/apt.12118. Epub 2012 Nov 5.

49.

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.

Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF.

J Crohns Colitis. 2013 Sep;7(8):636-43. doi: 10.1016/j.crohns.2012.09.016. Epub 2012 Oct 16.

PMID:
23078909
50.

MALDI-TOF mass spectrometry screening of cholelithiasis risk markers in the gene of HNF1alpha.

Richter D, Harsch S, Strohmeyer A, Hirobe-Jahn S, Schimmel S, Renner O, Müller O, Schäffeler E, Kratzer W, Schwab M, Stange EF.

J Proteomics. 2012 Jun 27;75(12):3386-99. doi: 10.1016/j.jprot.2012.04.036. Epub 2012 May 5.

PMID:
22569176

Supplemental Content

Loading ...
Support Center